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This study aimed to investigate whether carbamazepine, sodium valproate or phenobarbital as monotherapy in ambulatory
epileptic children with adequate sun exposure have some effect on their bone metabolism based on the determination of total
serum alkaline phosphatase (AP) levels and its bone isoenzyme activity. Blood samples were obtained from 118 epileptic
children (37 on carbamazepine, 47 on sodium valproate and 34 on phenobarbital) and from corresponding healthy controls
matched for age, gender and anthropometric parameters. AP and its liver, bone and intestinal isoenzyme levels, other common
biochemical markers of bone and liver metabolism and drug levels were measured in the study participants. Patients on
carbamazepine or phenobarbital had significantly elevated AP levels accompanied by increased bone and liver isoenzyme
activity compared to controls. An increase of bone AP isoenzyme values, correlated with the duration of treatment (r = 0.49,
P = 0.002), was found in children on sodium valproate without, however, a concomitant significant elevation of total AP values.
We conclude that children who receive antiepileptic drugs as monotherapy, even when residing in a Mediterranean country with
adequate sunlight, may have their bone metabolism affected as indicated by the elevated levels of bone AP isoenzyme. This
isoenzyme, but not total AP values, could therefore be used as a marker for the selection of patients who would be benefited by
a thorough evaluation of their bone metabolism profile.
c© 2002 Published by Elsevier Science Ltd on behalf of BEA Trading Ltd.
Key words: alkaline phosphatase; alkaline phosphatase isoenzymes; anticonvulsant drugs; bone metabolism; epileptic children.
INTRODUCTION
An increase in the activity of serum enzymes,
collectively termed alkaline phosphatase (AP), has
been reported in patients receiving antiepileptic
treatment1–3. However, AP isoenzyme activity has
been evaluated only in adult patients on anticonvul-
sant monotherapy4, 5. Several studies which assessed
bone metabolism status in adults and children on
antiepileptic drugs using other indicators than AP
isoenzyme activity, such as biochemical markers of
bone remodelling and/or calciotropic hormones, have
shown rather controversial results6–9. The diversity
of their findings could be attributed at least to some
extent to the heterogeneity of population samples
among different studies regarding the administered
medications (monotherapy or combination therapy),
the type of patients (ambulatory or institutionalized
patients) or both. Furthermore, taking into account
the well recognized association of sun exposure with
vitamin D metabolism10, 11, findings derived from a
population living in geographical areas with limited
exposure to sunshine may not be applicable for
inhabitants of sunny places.
In recent years, the assessment of bone mineral
density by dual energy X-ray absorptiometry (DEXA)
allowed the direct evaluation of bone mineralization
in children on antiepileptic drugs. However, even
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these studies disclose rather conflicting results12, 13
and the whole issue of a possible link between
antiepileptic drug administration and not clinically
apparent osteomalacia has therefore remained unre-
solved. This is still important as a possible undesirable
side effect of anticonvulsant medication on bone
metabolism could be prevented by the implementation
of appropriate measures. However, prerequisite for
such an intervention should be a sensitive and easily
measured biochemical marker for the evaluation of
bone metabolism alterations.
The objective of this study was to investigate
whether AP and/or its bone isoenzyme levels are
altered in children receiving as monotherapy car-
bamazepine, sodium valproate or phenobarbital and
could therefore be used as markers for their bone
metabolism monitoring. In order to evaluate whether
a possible elevation of total AP levels is a reflection
of liver or bone metabolism or both all the three
main fractions of AP (bone, liver, intestinal) were
measured and their relation with other commonly used
biochemical markers of liver and bone metabolism
was explored.
PATIENTS AND METHODS
The study population consisted of 118 ambulatory
children, aged from 12 months to 14 years, treated
for epilepsy with anticonvulsant monotherapy for a
minimum of 6 months. All children were otherwise
healthy and not receiving any other medication. None
of the participants had ever received an antiepileptic
drug other than the one which was given while
recruited in the study. One hundred and eighteen
clinically healthy children, based on history and
clinical examination, matched for age, gender and
anthropometric parameters (body weight and height),
served as controls. Epileptic children were divided into
three groups according to the antiepileptic medication
as follows: group1: carbamazepine (n = 37, mean
age ±SD = 8.08 ± 3.65 years), group 2: sodium
valproate (n = 47, age ±SD = 8.13± 3.9 years) and
group 3: phenobarbital (n = 34, mean age ±SD =
2.4 ± 1.6 years) and each group corresponded to a
matched for age, gender and anthropometric variables
group of healthy controls (group 1c, group 2c and
group 3c, respectively).
A blood sample was obtained after 12 hours
fasting in early morning, between 8.00 and 10.00
a.m. Serum calcium (Ca), phosphorus (P), gamma-
glutamyltransferase (γGT), alanine aminotransferase
(SGOT), aspartate aminotransferase (SGPT), AP, AP
bone, AP liver and AP intestinal isoenzyme levels
were determined in all specimens, whereas drug levels
were measured in epileptic children. An informed
parental consent was provided and the study was
approved by the Institutional Review Board.
Serum total AP was measured according to the
method recommended by the Dutch Society of
Clinical Chemistry, using commercially available kit
(Roche, Germany) and following the manufacturer’s
instructions. The method was adapted to a Hitachi
704 discrete analyser. Serum bone (AP-B), liver
(AP-L) and intestinal (AP-I) AP isoenzymes were
separated by electrophoresis on agarose gel and then
visualized and quantified using the Hydragel ISO-PAL
K20 kit (Sebia, France), following the manufacturer’s
recommendations. Samples were tested in duplicate
and the overall mean within-sample coefficient of
variation for the assay was 8.9%. Serum Ca, P,
γGT, SGOT, SGPT, and drug levels were measured
according to the usual standard methods.
For the statistical analysis a P value <0.05 was
considered as statistically significant.
RESULTS
Total AP, AP-B and AP-L isoenzyme levels were
significantly higher among children receiving car-
bamazepine compared to the corresponding group
of controls (Table 1). Total AP levels correlated
significantly to both bone and liver AP enzymes
(r = 0.96, P < 0.001; r = 0.41, P = 0.013,
respectively). Ca, P, SGOT, SGPT did not show any
significant difference whereas γGT was significantly
higher in children on carbamazepine (mean value
±SD = 23.7 ± 9.0 IU/l vs. 10.6 ± 5.9 IU/l, P <
0.001). Children on phenobarbital had significantly
higher total AP and AP bone and liver isoenzyme
levels compared to controls. Serum γGT levels were
also significantly higher in the phenobarbital group
compared to controls (mean value ±SD = 19 ±
5.7 IU/l vs. 8.9± 2.4 IU/l, P = 0.001, respectively),
whereas the values of Ca, P, SGOT and SGPT
did not show any significant difference. Children
receiving sodium valproate had significantly elevated
AP-B without any difference with respect to Ca, P,
SGOT, SGPT and γGT. There was no correlation
of drug levels with the total AP and its isoenzyme
activity irrespective of the type of antiepileptic
drug. Furthermore, there was no association of the
duration of treatment with the AP and its isoenzyme
activity within the groups of children who received
carbamazepine or phenobarbital but there was a
substantial and significant correlation of the duration
of treatment with bone alkaline levels (r = 0.49,
P = 0.002) in children on sodium valproate.
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Table 1: Serum AP and its isoenzyme levels (mean values ± SD) in epileptic children receiving antiepileptic monotherapy and
their corresponding controls.
Treatment AP AP-bone AP-liver AP-intestinal
(serum drug levels n (IU/l) P (IU/l) P (IU/l) P (IU/l) P
mean ± SD in mg l−1)
Carbamazepine 37 233.3± 70.4 186.3± 64.2 33.9± 17.4 12.2± 7.8
(6.8± 0.26) 0.001 0.001 0.001 NS
Controls 37 145.3± 54.0 86.2± 25.2 19.2± 11.5 15.3± 10.0
Phenobarbital 34 227.0± 48.9 0.001 176.8± 46.0 0.02 36.5± 23.2 0.03 12.0± 7.4 NS
(15.2± 0.78)
Controls 34 156.7± 64.5 138.0± 78.5 28.0± 23.1 4.9± 11.4
Sodium valproate 47 162.3± 71.8 NS 127.9± 58.2 0.02 21.0± 12.7 NS 11.9± 12.7 NS
(59.1± 2.7)
Controls 47 144.9± 53.3 87.5± 24.6 18.8± 11.1 15.0± 9.6
P values derived from Student’s t-test.
DISCUSSION
The issue of whether or not certain antiepileptic drugs
affect the bone metabolism of the recipients remains
rather controversial1–9. In this study we attempted
to investigate whether AP and its isoenzyme activity
indicate any alterations of bone metabolism in children
on antiepileptic medications. It was previously shown
that biochemical indices of osteomalacia such as
serum calcium and AP were related to bone mineral
content measured by photon absorptiometry14. We
consider AP as the most appropriate marker for this
purpose, as it is more sensitive compared to serum
calcium levels, it can be easily measured and therefore
any inferences from this study could be applicable
in clinical practice. Although AP originates from
different tissues, liver and bone isoenzymes are the
most abundant parts of the total AP activity in the
sera15. Therefore total AP levels mainly reflect hepatic
and bone metabolism both of which may be affected
by antiepileptic drugs. The determination of these
isoenzymes makes it feasible to elucidate whether AP
alterations are attributed to modification of liver or
bone metabolism or both.
To the best of our knowledge this is the first
study that evaluates AP isoenzyme activity in children
on carbamazepine or sodium valproate as monother-
apy. Similar studies have also been conducted by
other investigators16, 17 in children, ambulatory or
institutionalized, who, in contrast to our population,
had received anticonvulsant medications in various
combinations and not as monotherapy. Our study has
the advantage of the homogeneity of the participating
population within each group with respect to the type
of administered medication. Although confounding
could be raised as a concern for the interpretation of
the results, the selection of controls matching for age,
gender as well as anthropometric variables and the
fact that they did not differ from cases with respect to
sunshine exposure makes unlikely the possibility that
the validity of our findings is subjected to the effect of
any known confounder.
Our findings indicate that children on carba-
mazepine have elevated AP values due to both
altered liver and bone function as both bone and
liver alkaline isoenzymes were increased. Therefore
AP itself cannot be used as a marker for routine
monitoring of this risk as the elevation of AP may
simply reflect the influence of carbamazepine on
liver function. For this reason the determination
of AP isoenzymes seems to be mandatory for the
monitoring of bone metabolism alterations in patients
on carbamazepine. It is beyond the objective and
ability of this study to evaluate to what extent
elevated bone AP levels correlate to a clinically
important impact on bone metabolism. A recent
study, however, using biochemical markers of bone
formation and resorption suggests that carbamazepine
administration may cause an increased bone turnover
and not a reduced bone formation18. Altay et al.12
also suggested that carbamazepine does not affect
the bone mineral density of the recipients. However,
as these results were derived from studies with a
limited number of patients they do not constitute
enough evidence for the clinician not to consider the
possibility of vitamin D supplementation for some
patients on carbamazepine.
The elevation of bone AP fraction in patients on
sodium valproate which was not accompanied by a
significant elevation of total AP suggests that sodium
valproate administration does have an impact on
bone mineral metabolism in ambulatory children and
that normal total AP levels could not exclude the
possibility that the respective bone fraction may be
high. The increase of bone AP isoenzyme in this
study group would have been rather expected as
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decreased bone mineralization evaluated by DEXA or
biochemical markers has been observed in children
on sodium valproate even though treatment has been
administered for a rather short period of time13. The
fact that bone AP fraction correlated with duration of
treatment in this group indicates that monitoring of
these patients with markers of bone metabolism should
be performed on a regular basis.
Children on phenobarbital in our study showed
significantly elevated AP levels as well as bone
and liver AP isoenzymes. Our findings are in
accordance with those reported by Hahn et al.19
who also showed a significant reduction in bone
mass with a concomitant elevation of total AP, liver
and bone AP in outpatient children who received
phenobarbital and diphenylhydantoin either singly
or in combination. However, in their analysis they
treated the monotherapy group as a whole irrespective
of the type of medication administered. Therefore
although they clarified that no significant differences
were observed between the phenobarbital and the
diphenylhydantoin groups, it remains rather difficult
to extract definite conclusions with respect to the effect
of phenobarbital on bone metabolism out of that study.
In conclusion, AP bone isoenzyme activity, but
not total serum AP levels, could be considered
as a useful marker for the monitoring of bone
metabolism alterations in children on antiepileptic
drug monotherapy. Until more evidence is available
it seems that periodic monitoring is necessary for
patients on sodium valproate even when the initial
evaluation reveals normal bone AP isoenzyme activity.
Further investigation with serum vitamin D metabolite
concentrations and bone mineral density, where
available, may be appropriate in patients with raised
AP values in order to identify those who necessitate
prophylactic vitamin D supplementation.
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